BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter earnings report may be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/ve8zytc3/. A webcast repla ...

Core Viewpoint - Amwell is set to report its second quarter 2025 operating results on August 5, 2025, after market hours, followed by a live conference call to discuss the results and provide a business update [1]. Company Overview - Amwell provides a comprehensive SaaS-based software platform aimed at technology-enabled healthcare, facilitating better access to convenient, affordable, and effective care for patients [3]. - The platform integrates software and services that support various clinical programs, allowing for personalized access to diverse healthcare services [3]. - Amwell has been operational for nearly two decades, serving major healthcare organizations in the U.S. and globally, and is capable of delivering care to millions of patients [3]. Upcoming Events - Company executives will participate in investor conferences, including one-on-one meetings at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 9 [4].

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $66.8 million, a 12% increase compared to Q1 2024, and a 25% increase when normalizing for the sale of Amwell Psychiatric Care [21] - Subscription software revenue accounted for 48% of total revenue at $32.2 million, up 30% year-over-year [22] - Adjusted EBITDA improved to negative $12.2 million, compared to negative $45.6 million in Q1 2024, indicating a significant reduction in losses [26] Business Line Data and Key Metrics Changes - The number of completed visits in Q1 was approximately 1.3 million, which is about 23% lower than the previous year, but normalized for APC, it was 21% lower [22] - AMG's visit revenue trended 14.3% lower than last year at $26.6 million, but normalized for APC, visits were higher by 6.6% [23] - CarePoint revenue increased to $8 million from $4.9 million in the previous quarter, reflecting variable revenues due to consumer buying patterns [24] Market Data and Key Metrics Changes - The military health system is now fully utilizing Amwell's platform for virtual visits, positioning the company strongly in the federal market [10] - Patient and provider satisfaction on the platform is reported at over 90% [11] - The company anticipates a significant shift towards technology-enabled care as consumer demand for online services increases [14] Company Strategy and Development Direction - The company aims to achieve positive cash flow from operations by 2026, focusing on increasing the mix of subscription software revenues [20] - Amwell is positioned as a key enabler in the shift towards technology-enabled care, providing a unified platform for payers and providers [15] - The company is committed to driving efficiencies and optimizing cash flow while expanding its market reach [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing partnership with the DHA and the renewal of the contract with Leidos, indicating a strong future outlook [29] - The company is optimistic about its ability to navigate macroeconomic challenges, viewing its platform as a solution for efficiency and cost savings [48] - Management highlighted the importance of their unique offerings in a growing market, with expectations for continued growth and expansion [19] Other Important Information - The company ended Q1 2025 with $222 million in cash and marketable securities and zero debt [26] - The guidance for 2025 remains unchanged, with expected revenue in the range of $250 million to $260 million, excluding anticipated revenue from APC [27] Q&A Session Summary Question: Can you talk about bookings trends for CONVERGE and the impact of Dan's hire? - Management noted good receptivity to the AMOLED platform beyond DHA, with a focus on improving consumer experience and data infrastructure [35] Question: Is the current gross margin rate sustainable for the rest of the year? - Management indicated that gross margins should improve as software revenues increase, with expectations of reaching 75-90% margins [42] Question: Have macroeconomic factors impacted sales timelines? - Management acknowledged market uncertainty but noted that their platform is seen as part of the solution, leading to an acceleration in interest [48] Question: What is the status of the DHA contract and other government opportunities? - Management expects no significant changes in the economics of the DHA contract and highlighted their successful execution as a competitive advantage for future opportunities [55] Question: What is the company's exposure to tariffs? - Management stated that direct exposure to tariffs is minimal, as most software is developed in the U.S., and emphasized the platform's ROI for clients [58] Question: How is churn being managed, and what is the outlook for the selling season? - Management reported lower-than-expected churn and noted increased interest from both payers and health systems, indicating a positive outlook for the selling season [83]

Core Insights - Amwell, a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, announced its financial results for the first quarter ended March 31, 2025 [1] Company Overview - Amwell offers a single, comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3] - The platform includes software and services that support various clinical programs, providing unified, personalized access to diversified clinical programs across the care continuum [3] - Amwell has been operational for almost two decades, serving some of the largest healthcare organizations in the U.S. and worldwide, enabling care for millions of patients [3]

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, offering a unified care platform for payers and health systems [1] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [1] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [1] Upcoming Events - Mark Hirschhorn, CFO and COO of Amwell, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference on May 8 [4] - On June 24, Hirschhorn will also participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City [4]